FILING ANALYSIS · MONDAY, NOVEMBER 16

ENANTA PHARMACEUTICALS INC ENTA — 8-K: Results of Operations and Financial Condition

neutral

Enanta Pharmaceuticals reported fiscal Q4 and year-end results with total revenue of $12.9 million and $63.0 million, respectively, and a cash runway expected to fund operations into fiscal 2029, but the decrease in revenue due to a decline in AbbVie's sales of MAVYRET/MAVIRET may impact investor sentiment

The filing

8-K - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

Read the filing on SEC EDGAR →

How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.

Get filings like this every market day

The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.

Subscribe free →
All analyses · Earnings today · Latest brief · Track record
© 2026 Dutchcode B.V. · Built by
Blinkof.ai verified — grade A+